New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment ...

Structure Therapeutics recently reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and ...

It is a characteristic of cell membrane receptors, which is shared by GPCRs along with G-protein associates. The process of receptor oligomerization is assisted by the cell thermodynamics as well as ...

For decades, dopamine signaling was viewed primarily through the lens of motor vigor—how fast or forcefully one moves. However, a landmark 2025 study from Karolinska Institutet published in Nature ...

Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.